Table 2.
Key randomized clinical trials evaluating new antiretrovirals: pregnant women
| Clinical trial | Treatment arms | Inclusion | Objective | Results |
| Dolphin-1 | 2NRTI + EFV | Pregnant women | Efficacy | 2018 |
| N = 60 | 2NRTI + DTG | (Uganda) | Birth outcomes | |
| Dolphin-2 | 2NRTI + EFV | Pregnant women | Efficacy | 2020 |
| N = 250 | 2NRTI + DTG | (Uganda) | Birth outcomes | |
| VESTED | TDF/FTC/EFV | Pregnant women | Efficacy | 2020 |
| N = 549 | TDF/FTC/DTG | (International) | Birth outcomes | |
| TAF/FTV/DTG | ||||
| SSAT 063 | 2NRTI + EFV400 | Pregnant women | PK, outcomes | 4Q17 |
| N = 25 |
2NRTI, two nucleoside analogues; DTG, dolutegravir; EFV, efavirenz; EFV400, efavirenz 400 mg; FTC, emtricitabine; PK, Pharmacokinetics; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.